US Patent 11780843 Compounds active towards nuclear receptors

Is a

Patent

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11780843

Patent Inventor Names

Ian Sarvary

Montserrat Erra Solà

Alex Haahr Gouliaev

Joan Taltavull Moll

Luigi Piero Stasi

Sanne Schrøder Glad

Thomas Franch

Paul Robert Eastwood

Date of Patent

October 10, 2023

Patent Application Number

17218543

Date Filed

March 31, 2021

Patent Citations

‌

US Patent 10683393 Methods of solid freeform fabrication

‌

US Patent 10683293 Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases

‌

US Patent 10689383 Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases

‌

US Patent 7931909 Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates

‌

US Patent 8338439 2,4-disubstituted pyrimidines useful as kinase inhibitors

Patent Primary Examiner

CPC Code

Patent abstract

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 11780843 Compounds active towards nuclear receptors

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 11780843 Compounds active towards nuclear receptors